WS #15234
Nike's stock is plunging to a 13-year low as weak guidance tests the market's patience with the CEO's turnaround efforts, leading to its removal from the S&P 100. In contrast, smaller caps like Scienture are seeing institutional adoption for their hypertension drugs, and Cupid Limited is raising annual guidance. The divergence highlights a market focused on specific catalysts rather than broad consumer discretionary strength.
Corporate Earnings and Guidance
Nike's stock is plunging to a 13-year low as weak guidance tests the market's patience with the CEO's turnaround efforts, leading to its removal from the S&P 100. In contrast, smaller caps like Scienture are seeing institutional adoption for their hypertension drugs, and Cupid Limited is raising annual guidance. The divergence highlights a market focused on specific catalysts rather than broad consumer discretionary strength.